CCCC · C4 Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Andrew Hirsch President & CEO | ▼ Sell | Tax Withholding | 1,074,934 Shares held | 2/15/2026 | View profile |
| Prokupets Elena Director | ▼ Sell | Open Market | 503,126 Shares held | 9/27/2021 | View profile |
| Kendra Adams Chief Financial Officer | ▼ Sell | Tax Withholding | 382,323 Shares held | 9/18/2026 | View profile |
| Leonard Reyno Chief Medical Officer | ▼ Sell | Tax Withholding | 372,406 Shares held | 7/10/2026 | View profile |
| Paige Mahaney Chief Scientific Officer | ▼ Sell | Tax Withholding | 336,910 Shares held | 2/14/2026 | View profile |
| Kelly Schick Chief People Officer | ▼ Sell | Tax Withholding | 299,881 Shares held | 2/14/2026 | View profile |
| Scott N. Boyle Chief Business Officer | ▼ Sell | Tax Withholding | 298,801 Shares held | 2/14/2026 | View profile |
| Fisher Stewart Chief Scientific Officer | ▼ Sell | Tax Withholding | 130,710 Shares held | 9/16/2024 | View profile |
| Siegel Jolie Chief Legal Officer | ▼ Sell | Tax Withholding | 107,939 Shares held | 2/14/2025 | View profile |
| Donna Roy Grogan Director | ▲ Buy | Grant | 79,471 Shares held | 10/1/2026 | View profile |
| Kenneth Carl Anderson Director | ▲ Buy | Grant | 75,612 Shares held | 10/1/2026 | View profile |
| Mark Mossler Chief Accounting Officer | ▼ Sell | Tax Withholding | 71,916 Shares held | 2/14/2026 | View profile |
| White Lauren Chief Financial Officer | ▼ Sell | Tax Withholding | 32,686 Shares held | 8/30/2023 | View profile |
| Dubin Glenn Director | ▲ Buy | Grant | 22,075 Shares held | 4/1/2024 | View profile |
| Crystal Adam President, R&D | ▼ Sell | Tax Withholding | 20,097 Shares held | 1/30/2023 | View profile |
| Salter Malcolm Director | ▲ Buy | Grant | 11,380 Shares held | 1/4/2022 | View profile |
| Koppikar Utpal Director | ▲ Buy | Open Market | 5,667 Shares held | 2/8/2023 | View profile |
| COHEN MARC A Director | ▲ Buy | Grant | 1,118 Shares held | 1/4/2022 | View profile |
| COHEN ALAIN J Director | ▲ Buy | Grant | 928 Shares held | 4/4/2022 | View profile |
Transaction History
| Kenneth Carl Anderson | ▲ Buy | Grant | 3,662 | $11K | 10/1/2026 |
| Donna Roy Grogan | ▲ Buy | Grant | 4,618 | $15K | 10/1/2026 |
| Kendra Adams | ▲ Buy | Option Exercise | 6,250 | $0 | 9/18/2026 |
| Kendra Adams | ▼ Sell | Tax Withholding | 2,775 | $9K | 9/18/2026 |
| Leonard Reyno | ▲ Buy | Option Exercise | 15,325 | $0 | 7/10/2026 |
| Leonard Reyno | ▼ Sell | Tax Withholding | 7,397 | $30K | 7/10/2026 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 2,650 | $12K | 7/1/2026 |
| Donna Roy Grogan | ▲ Buy | Grant | 3,341 | $14K | 7/1/2026 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 1,070 | $2K | 6/1/2026 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 4,259 | $11K | 4/1/2026 |
| Donna Roy Grogan | ▲ Buy | Grant | 5,370 | $14K | 4/1/2026 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 20,400 | $0 | 2/15/2026 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 9,057 | $17K | 2/15/2026 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 20,950 | $0 | 2/14/2026 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 7,269 | $14K | 2/14/2026 |
| Paige Mahaney | ▲ Buy | Option Exercise | 7,050 | $0 | 2/14/2026 |
| Paige Mahaney | ▼ Sell | Tax Withholding | 2,446 | $5K | 2/14/2026 |
| Kelly Schick | ▲ Buy | Option Exercise | 20,950 | $0 | 2/14/2026 |
| Kelly Schick | ▼ Sell | Tax Withholding | 7,269 | $14K | 2/14/2026 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 81,725 | $0 | 2/14/2026 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 39,154 | $74K | 2/14/2026 |
| Leonard Reyno | ▲ Buy | Option Exercise | 30,950 | $0 | 2/14/2026 |
| Leonard Reyno | ▼ Sell | Tax Withholding | 16,579 | $31K | 2/14/2026 |
| Kendra Adams | ▲ Buy | Option Exercise | 30,950 | $0 | 2/14/2026 |
| Kendra Adams | ▼ Sell | Tax Withholding | 15,381 | $29K | 2/14/2026 |
| Mark Mossler | ▲ Buy | Option Exercise | 9,420 | $0 | 2/14/2026 |
| Mark Mossler | ▼ Sell | Tax Withholding | 3,268 | $6K | 2/14/2026 |
| Scott N. Boyle | ▲ Buy | Grant | 200,000 | $0 | 2/13/2026 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 5,000 | $0 | 2/13/2026 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 1,735 | $3K | 2/13/2026 |
| Paige Mahaney | ▲ Buy | Grant | 240,000 | $0 | 2/13/2026 |
| Kelly Schick | ▲ Buy | Grant | 200,000 | $0 | 2/13/2026 |
| Kelly Schick | ▲ Buy | Option Exercise | 5,000 | $0 | 2/13/2026 |
| Kelly Schick | ▼ Sell | Tax Withholding | 1,735 | $3K | 2/13/2026 |
| Andrew Hirsch | ▲ Buy | Grant | 700,000 | $0 | 2/13/2026 |
| Leonard Reyno | ▲ Buy | Grant | 240,000 | $0 | 2/13/2026 |
| Kendra Adams | ▲ Buy | Grant | 240,000 | $0 | 2/13/2026 |
| Kendra Adams | ▲ Buy | Option Exercise | 3,750 | $0 | 2/13/2026 |
| Kendra Adams | ▼ Sell | Tax Withholding | 1,863 | $4K | 2/13/2026 |
| Mark Mossler | ▲ Buy | Grant | 56,980 | $0 | 2/13/2026 |
| Leonard Reyno | ▼ Sell | Open Market | 10,000 | $22K | 1/16/2026 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 5,958 | $11K | 1/2/2026 |
| Donna Roy Grogan | ▲ Buy | Grant | 7,513 | $15K | 1/2/2026 |
| Paige Mahaney | ▲ Buy | Option Exercise | 19,200 | $0 | 10/28/2025 |
| Paige Mahaney | ▼ Sell | Tax Withholding | 5,644 | $15K | 10/28/2025 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 5,349 | $12K | 10/1/2025 |
| Donna Roy Grogan | ▲ Buy | Grant | 6,740 | $14K | 10/1/2025 |
| Kendra Adams | ▲ Buy | Option Exercise | 6,250 | $0 | 9/18/2025 |
| Kendra Adams | ▼ Sell | Tax Withholding | 2,775 | $9K | 9/18/2025 |
| Leonard Reyno | ▼ Sell | Tax Withholding | 7,382 | $15K | 7/10/2025 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 7,616 | $12K | 7/1/2025 |
| Donna Roy Grogan | ▲ Buy | Grant | 9,609 | $15K | 7/1/2025 |
| Donna Roy Grogan | ▲ Buy | Grant | 9,581 | $14K | 4/1/2025 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 7,841 | $11K | 4/1/2025 |
| Scott N. Boyle | ▼ Sell | Open Market | 669 | $2K | 2/18/2025 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 9,370 | $30K | 2/15/2025 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 2,914 | $9K | 2/14/2025 |
| Kelly Schick | ▼ Sell | Tax Withholding | 2,368 | $8K | 2/14/2025 |
| Kendra Adams | ▼ Sell | Tax Withholding | 4,559 | $14K | 2/14/2025 |
| Paige Mahaney | ▲ Buy | Grant | 28,200 | $0 | 2/14/2025 |
| Leonard Reyno | ▲ Buy | Grant | 87,100 | $0 | 2/14/2025 |
| Leonard Reyno | ▼ Sell | Tax Withholding | 5,145 | $16K | 2/14/2025 |
| Kendra Adams | ▲ Buy | Grant | 87,100 | $0 | 2/14/2025 |
| Kelly Schick | ▲ Buy | Grant | 56,500 | $0 | 2/14/2025 |
| Andrew Hirsch | ▲ Buy | Grant | 223,500 | $0 | 2/14/2025 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 12,847 | $41K | 2/14/2025 |
| Siegel Jolie | ▲ Buy | Grant | 56,500 | $0 | 2/14/2025 |
| Scott N. Boyle | ▲ Buy | Grant | 56,500 | $0 | 2/14/2025 |
| Scott N. Boyle | ▼ Sell | Open Market | 490 | $2K | 2/14/2025 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 2,368 | $8K | 2/14/2025 |
| Mark Mossler | ▼ Sell | Tax Withholding | 1,586 | $5K | 2/14/2025 |
| Kendra Adams | ▼ Sell | Tax Withholding | 1,863 | $6K | 2/13/2025 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 2,135 | $7K | 2/13/2025 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 1,735 | $6K | 2/13/2025 |
| Kelly Schick | ▼ Sell | Tax Withholding | 1,735 | $6K | 2/13/2025 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 3,074 | $11K | 1/2/2025 |
| Donna Roy Grogan | ▲ Buy | Grant | 3,757 | $14K | 1/2/2025 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 1,102 | $7K | 11/7/2024 |
| Kendra Adams | ▲ Buy | Option Exercise | 3,750 | — | 11/7/2024 |
| Kendra Adams | ▼ Sell | Tax Withholding | 1,102 | $7K | 11/7/2024 |
| Kelly Schick | ▼ Sell | Tax Withholding | 1,102 | $7K | 11/7/2024 |
| Siegel Jolie | ▲ Buy | Option Exercise | 3,750 | — | 11/7/2024 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 1,102 | $7K | 11/7/2024 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 12,500 | — | 11/7/2024 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 3,750 | — | 11/7/2024 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 5,550 | $34K | 11/7/2024 |
| Kelly Schick | ▲ Buy | Option Exercise | 3,750 | — | 11/7/2024 |
| Paige Mahaney | ▲ Buy | Grant | 76,800 | $0 | 10/28/2024 |
| Donna Roy Grogan | ▲ Buy | Grant | 2,474 | $14K | 10/1/2024 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 2,023 | $11K | 10/1/2024 |
| Kendra Adams | ▼ Sell | Tax Withholding | 1,837 | $12K | 9/18/2024 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 3,329 | $21K | 9/16/2024 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 |
| Kendra Adams | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 |
| Kendra Adams | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 |
| Fisher Stewart | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 |
| Fisher Stewart | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 |
| Kelly Schick | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 |
| Kelly Schick | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 |
| Siegel Jolie | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 7,500 | — | 9/16/2024 |
| Leonard Reyno | ▼ Sell | Tax Withholding | 6,191 | $31K | 7/10/2024 |
| Donna Roy Grogan | ▲ Buy | Grant | 2,836 | $14K | 7/1/2024 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 2,320 | $11K | 7/1/2024 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 1,389 | $11K | 4/1/2024 |
| Dubin Glenn | ▲ Buy | Grant | 1,358 | $11K | 4/1/2024 |
| Donna Roy Grogan | ▲ Buy | Grant | 1,697 | $14K | 4/1/2024 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 6,560 | $52K | 2/15/2024 |
| Fisher Stewart | ▲ Buy | Grant | 27,300 | $0 | 2/14/2024 |
| Mark Mossler | ▲ Buy | Grant | 18,290 | $0 | 2/14/2024 |
| Andrew Hirsch | ▲ Buy | Grant | 103,400 | $0 | 2/14/2024 |
| Siegel Jolie | ▲ Buy | Grant | 27,300 | $0 | 2/14/2024 |
| Kelly Schick | ▲ Buy | Grant | 27,300 | $0 | 2/14/2024 |
| Kendra Adams | ▲ Buy | Grant | 36,700 | $0 | 2/14/2024 |
| Scott N. Boyle | ▲ Buy | Grant | 27,300 | $0 | 2/14/2024 |
| Leonard Reyno | ▲ Buy | Grant | 36,700 | $0 | 2/14/2024 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 1,735 | $11K | 2/13/2024 |
| Kelly Schick | ▼ Sell | Tax Withholding | 1,735 | $11K | 2/13/2024 |
| Kendra Adams | ▼ Sell | Tax Withholding | 1,301 | $8K | 2/13/2024 |
| Fisher Stewart | ▼ Sell | Tax Withholding | 2,255 | $15K | 2/13/2024 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 1,735 | $11K | 2/13/2024 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 1,725 | $11K | 1/2/2024 |
| Donna Roy Grogan | ▲ Buy | Grant | 2,108 | $14K | 1/2/2024 |
| Dubin Glenn | ▲ Buy | Grant | 1,687 | $11K | 1/2/2024 |
| Dubin Glenn | ▲ Buy | Grant | 6,470 | $11K | 10/2/2023 |
| Donna Roy Grogan | ▲ Buy | Grant | 8,089 | $14K | 10/2/2023 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 6,617 | $11K | 10/2/2023 |
| Kendra Adams | ▲ Buy | Grant | 25,000 | $0 | 9/18/2023 |
| Fisher Stewart | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 7,500 | — | 8/30/2023 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 2,205 | $6K | 8/30/2023 |
| Siegel Jolie | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 |
| White Lauren | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 |
| White Lauren | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 |
| Kelly Schick | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 |
| Kelly Schick | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 |
| Fisher Stewart | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 |
| Leonard Reyno | ▲ Buy | Grant | 61,300 | $0 | 7/10/2023 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 3,976 | $11K | 7/3/2023 |
| Donna Roy Grogan | ▲ Buy | Grant | 4,858 | $14K | 7/3/2023 |
| Dubin Glenn | ▲ Buy | Grant | 3,887 | $11K | 7/3/2023 |
| Dubin Glenn | ▲ Buy | Grant | 3,438 | $11K | 4/3/2023 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 3,516 | $11K | 4/3/2023 |
| Donna Roy Grogan | ▲ Buy | Grant | 4,298 | $14K | 4/3/2023 |
| Andrew Hirsch | ▲ Buy | Grant | 81,600 | $0 | 2/15/2023 |
| White Lauren | ▲ Buy | Grant | 26,000 | $0 | 2/13/2023 |
| Kelly Schick | ▲ Buy | Grant | 20,000 | $0 | 2/13/2023 |
| Fisher Stewart | ▲ Buy | Grant | 26,000 | $0 | 2/13/2023 |
| Siegel Jolie | ▲ Buy | Grant | 20,000 | $0 | 2/13/2023 |
| Scott N. Boyle | ▲ Buy | Grant | 20,000 | $0 | 2/13/2023 |
| Koppikar Utpal | ▲ Buy | Open Market | 5,667 | $32K | 2/8/2023 |
| White Lauren | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 |
| Andrew Hirsch | ▼ Sell | Tax Withholding | 4,319 | $34K | 1/30/2023 |
| Siegel Jolie | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 |
| Kelly Schick | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 |
| Kelly Schick | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Fisher Stewart | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Fisher Stewart | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 |
| Siegel Jolie | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Crystal Adam | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Crystal Adam | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 |
| White Lauren | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 |
| Scott N. Boyle | ▼ Sell | Tax Withholding | 1,222 | $10K | 1/30/2023 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 12,500 | — | 1/30/2023 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 444 | $2K | 1/6/2023 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 268 | $565 | 1/6/2023 |
| Donna Roy Grogan | ▲ Buy | Grant | 1,763 | $11K | 1/3/2023 |
| Dubin Glenn | ▲ Buy | Grant | 1,725 | $11K | 1/3/2023 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 1,568 | $10K | 1/3/2023 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 267 | $563 | 10/3/2022 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 445 | $2K | 10/3/2022 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 1,150 | $10K | 10/3/2022 |
| Dubin Glenn | ▲ Buy | Grant | 1,265 | $11K | 10/3/2022 |
| Donna Roy Grogan | ▲ Buy | Grant | 819 | $7K | 10/3/2022 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 535 | $1K | 7/15/2022 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 889 | $4K | 7/15/2022 |
| Dubin Glenn | ▲ Buy | Grant | 1,372 | $11K | 7/1/2022 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 1,246 | $10K | 7/1/2022 |
| Siegel Jolie | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| Crystal Adam | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| Kelly Schick | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| Fisher Stewart | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| White Lauren | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| Scott N. Boyle | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 |
| Andrew Hirsch | ▲ Buy | Option Exercise | 12,500 | — | 5/25/2022 |
| Fisher Stewart | ▲ Buy | Option Exercise | 25,928 | $129K | 4/12/2022 |
| Fisher Stewart | ▲ Buy | Option Exercise | 2,156 | $8K | 4/12/2022 |
| Andrew Hirsch | ▲ Buy | Open Market | 10,000 | $84K | 4/12/2022 |
| Dubin Glenn | ▲ Buy | Grant | 379 | $10K | 4/4/2022 |
| Kenneth Carl Anderson | ▲ Buy | Grant | 341 | $9K | 4/4/2022 |
| COHEN ALAIN J | ▲ Buy | Grant | 388 | $10K | 4/4/2022 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 803 | $2K | 1/26/2022 |
| Kenneth Carl Anderson | ▲ Buy | Option Exercise | 1,334 | $7K | 1/26/2022 |
| Salter Malcolm | ▲ Buy | Grant | 428 | $14K | 1/4/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.